MOD GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== NCBI identifiers === The NCBI defined a standard for the unique identifier used for the sequence (SeqID) in the header line. This allows a sequence that was obtained from a database to be labelled with a reference to its database record. The database identifier format is understood by the NCBI tools like makeblastdb and table2asn. The following list describes the NCBI FASTA defined format for sequence identifiers.
=== Western Transvaal === The Boer commandos in the Western Transvaal were very active after September 1901. Several battles were fought there between September 1901 and March 1902. At Moedwil on 30 September 1901 and again at Driefontein on 24 October, General Koos De La Rey's forces attacked British camps and outposts but were forced to withdraw after the British offered strong resistance. From late 1901 to early 1902, a time of relative quiet descended on the western Transvaal. February 1902 saw the next major battle in that region. On 25 February, De La Rey attacked a British column under Lieutenant-Colonel S. B. von Donop at Ysterspruit near Wolmaransstad. De La Rey succeeded in capturing many men and ammunition. The Boer attacks prompted Lord Methuen, the British second-in-command after Kitchener, to move his column from Vryburg to Klerksdorp to deal with De La Rey. On the morning of 7 March 1902, the Boers attacked the rear guard of Methuen's moving column at Tweebosch. Confusion reigned in British ranks and Methuen was wounded and captured by the Boers. The Boer victories in the west led to stronger action by the British. In the second half of March 1902, British reinforcements were sent to the Western Transvaal under the direction of Ian Hamilton. The opportunity the British were waiting for arose on 11 April 1902 at Rooiwal, where a commando led by General Jan Kemp and Commandant Potgieter attacked a superior force under Kekewich.
== Z == Shuguang Zhang (PhD 1988). American biochemist at the Massachusetts Institute of Technology, known for his discovery of self-assembling peptides. Guggenheim Fellow and Member, Austrian Academy of Sciences. Donald Zilversmit (1919–2010). Dutch-American nutritional biochemist at Cornell University, with many contributions to the understanding of the relationship between diet and cardiovascular disease. Member Natl. Acad. Sci. USA.
=== Speed: Bubnoff unit === The Bubnoff unit is defined as 1 micrometre per year (3.169×10−14 m/s), or one millimeter per 1,000 years. It is employed in geology to measure rates of lowering of earth surfaces due to erosion.
SNP genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNPs are one of the most common types of genetic variation. An SNP is a single base pair mutation at a specific locus, usually consisting of two alleles (where the rare allele frequency is > 1%). SNPs are found to be involved in the etiology of many human diseases and are becoming of particular interest in pharmacogenetics. Because SNPs are conserved during evolution, they have been proposed as markers for use in quantitative trait loci (QTL) analysis and in association studies in place of microsatellites. The use of SNPs is being extended in the HapMap project, which aims to provide the minimal set of SNPs needed to genotype the human genome. SNPs can also provide a genetic fingerprint for use in identity testing. The increase of interest in SNPs has been reflected by the furious development of a diverse range of SNP genotyping methods.
Sources: en.wikipedia.org
=== Brand names === Tranexamic acid is marketed in the US and Australia in tablet form as Lysteda and in Australia, Sweden and Jordan it is marketed in an IV form and tablet form as Cyklokapron, in the UK and Sweden as Cyclo-F. In the UK it is also marketed as Femstrual, in Asia as Transcam, in Bangladesh as Intrax & Tracid, in India as Pause, in Pakistan as Transamin, in Indonesia as Kalnex, in South America as Espercil, in Japan as Nicolda, in France, Poland, Belgium, and Romania as Exacyl and in Egypt as Kapron. In the Philippines, its capsule form is marketed as Hemostan and in Israel as Hexakapron.
== Bioanalytical organisations == There are several national and international bioanalytical organisations active throughout the world. Often they are part of a bigger organisation, e.g. Bioanalytical Focus Group and Ligand Binding Assay Bioanalytical Focus Group, which are both within the American Association of Pharmaceutical Scientists (AAPS) and FABIAN, a working group of the Analytical Chemistry Section of the Royal Netherlands Chemical Society. The European Bioanalysis Forum (EBF), on the other hand, is independent of any larger society or association.
Play Australian rules football at any level; Enter the club premises or clubrooms on game day; Train under the direction of a club-devised program; or Return to their clubs' training sessions until two months before their bans expired. Because of these limitations, the bans also covered most forms of coaching. As such, two former players (Mark McVeigh and Henry Slattery) who were employed as non-playing coaches were suspended from their jobs, and players serving as playing coaches in country leagues were suspended from performing either function. The bans extended to any sport administered by a signatory to the WADA code, precluding active involvement in almost any organised sport during 2016. Players were not completely banned from involvement with the AFL, and were permitted to:
=== Research directions === Several challenges remain to be addressed for widespread adoption and integration of theranostics into routine clinical practice. Regulatory considerations will play a role in ensuring the safety, efficacy, and quality of theranostic agents and technologies. Harmonization of regulations across different countries and regions is necessary to facilitate global implementation. Cost-effectiveness is a significant challenge, as theranostic approaches can be expensive. Strategies to optimize resource utilization and reimbursement models have been discussed. Technical limitations, such as the development of more specific and sensitive imaging agents, improvement of imaging resolution and quality, and the integration of different imaging modalities, require ongoing research and technological advancements. Ethical considerations surrounding patient privacy, data security, and the responsible use of patient information need to be addressed.
Sources: en.wikipedia.org
PCP is both water- and lipid-soluble and is therefore distributed throughout the body quickly. PCP is metabolized into PCHP, PPC and PCAA. The drug is metabolized 90% by oxidative hydroxylation in the liver during the first pass. Metabolites are glucuronidated and excreted in the urine. Nine percent of ingested PCP is excreted in its unchanged form. When smoked, some of the compound is broken down by heat into 1-phenylcyclohexene (PC) and piperidine. The time taken before the effects of PCP manifest is dependent on the route of administration. The onset of action for inhalation occurs in 2–5 minutes, whereas the effects may take 15 to 60 minutes when ingested orally.
After exploring running in several previous cycles, in January 2007, Biden declared his candidacy in the 2008 elections. Biden focused on the Iraq War, his record as chairman of major Senate committees, and his foreign-policy experience. Biden was noted for his one-liners during the campaign; in one debate he said of Republican candidate Rudy Giuliani, "There's only three things he mentions in a sentence: a noun, and a verb and 9/11." Biden had difficulty raising funds, struggled to draw people to his rallies, and failed to gain traction against the high-profile candidacies of Barack Obama and Hillary Clinton. He never rose above single digits in national polls of the Democratic candidates. In the first contest on January 3, 2008, Biden placed fifth in the Iowa caucuses, garnering slightly less than one percent of the state delegates. He withdrew from the race that evening. Despite its lack of success, Biden's 2008 campaign raised his stature in the political world. In particular, it changed the relationship between Biden and Obama. Although they had served together on the Senate Foreign Relations Committee, they had not been close: Biden resented Obama's quick rise to political stardom, while Obama viewed Biden as garrulous and patronizing. Having gotten to know each other during 2007, Obama appreciated Biden's campaign style and appeal to working-class voters, and Biden said he became convinced Obama was "the real deal".
[We] have to act according not only to the facts but to the ... evidence. I am sure you understand that these are very grave accusations." The European Ombudsman, Emily O'Reilly, was, however critical of the response of Von der Leyen and fellow politicians and institutions, highlighting the lack of progress shown by von der Leyen following her pledge that transparency would be a core part of her mandate when she became European Commission President. O'Reilly called for a body to be created with real investigatory and sanctions powers. The Belgian Prime Minister, Alexander De Croo, was also critical of the European institutions in his response, stating that "Belgian justice is doing what, at first sight, the European Parliament hasn't done." "The European Parliament has a lot of means to regulate itself. It turns out that this is largely a system of auto-control based on voluntary efforts, which has clearly not been sufficient." Annalena Baerbock, the German Minister for Foreign Affairs, highlighted that the scandal is leading to concerns from citizens and affects the credibility and legitimacy of the institutions of the European Union. On 15 December the European People's Party (EPP) reacted by declaring, "We need to discuss hypocrisy ... This is an S&D scandal." In an attempt to focus the scandal on the Progressive Alliance of Socialists and Democrats Group (S&D), rather than the European Parliament as a whole, they continued, "There has been a consistent effort to turn #Qatargate into an institutional issue alone. But this scandal is not an orphan. ... It has an address.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.